Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia First-in-Human Study of ISH0613 in Healthy Subjects
NCT07516639Phase 1Not yet recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Single-ascending dose：ISH0613 with Single-ascending dose：Placebo (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events at day 57 and Injection site reactions assessments at day 57. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ISH0613
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07516639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516639.